Key result
TEE-guided fluoroscopy-free axillary Impella 5.5 implantation achieves 100% success without major complications.
Why the study?
Timely access to a hybrid operating room or C-arm fluoroscopy for urgent axillary Impella 5.5 implantation remains a barrier in cardiogenic shock.
Does fluoroscopy-free transesophageal echocardiography (TEE)-guided axillary Impella 5.5 implantation provide safe and successful mechanical circulatory support in adults with cardiogenic shock?
Does fluoroscopy-free transesophageal echocardiography (TEE)-guided axillary Impella 5.5 implantation provide safe and successful mechanical circulatory support in adults with cardiogenic shock?
Transesophageal echocardiography-guided, fluoroscopy-free axillary Impella 5.5 implantation is a feasible and safe technique that may prevent critical delays in mechanical circulatory support for cardiogenic shock.
Supports feasibility of fluoroscopy-free TEE-guided Impella 5.5 implantation; hypothesis-generating and requires prospective validation before adoption.
Delays in mechanical circulatory support (MCS) for cardiogenic shock can be critical. However, timely access to a hybrid operating room or C-arm fluoroscopy for urgent axillary Impella 5.5 (Abiomed, Danvers, MA) implantation remains a barrier. To address this, we developed a fluoroscopy-free axillary Impella 5.5 implantation technique using transesophageal echocardiography (TEE) guidance. From January 2023 to November 2024, 19 adults underwent the procedure. A preoperative flowchart ensured appropriate selection, with the right axillary artery as the preferred access. Transesophageal echocardiography-guided pigtail advancement, valve crossing, and device positioning. All implantations (100%) were successful without conversion to fluoroscopy-guided or ECMO. There were no strokes or major complications. All patients had optimal positioning and rapid hemodynamic improvement. These findings support the feasibility and safety of TEE-guided, fluoroscopy-free Impella 5.5 implantation. It offers a significant benefit for earlier implantation of MCS in patients with cardiogenic shock, especially in settings where limited or delayed access to fluoroscopic imaging resources is a barrier to timely intervention.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2026) studied this question. The fluoroscopy-free axillary Impella 5.5 implantation using transesophageal echocardiography was successful in 100% of cases with no major complications or strokes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: